Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 continuation study in adults with ulcerative colitis or Crohn's disease
NL-OMON59459Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zasocitinib in autoimmune colitis and Crohn's disease, sponsored by Takeda. Started Dec 2025; status: recruiting.
02
Drugs
zasocitinib
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON59459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59459.